Dr Kam Lally outlines how practitioners can use botulinum toxin to manage rosacea
Rosacea is a chronic dermatological condition characterised by facial erythema, flushing and inflammatory lesions. Traditional treatments often yield inconsistent results, prompting exploration of alternative therapies.
Botulinum toxin type A (BoNT-A), widely recognised for its neuromodulatory properties, has emerged as a potential off-label treatment for rosacea.1 This article reviews the current evidence on the efficacy and safety of BoNT-A in managing rosacea symptoms.
Understanding rosacea Rosacea affects approximately 5% of the global population, predominantly impacting individuals with fair skin.2 The condition manifests through persistent facial redness, visible blood vessels and sometimes acne-like breakouts.2
There are four main types of rosacea, each with distinct characteristics:3
1. Erythematotelangiectatic rosacea (ETR)
· Persistent facial redness (erythema)
· Visible blood vessels (telangiectasia)
